Journal of the National Cancer Institute Advance Access originally published online on August 8, 2007
JNCI Journal of the National Cancer Institute 2007 99(16):1248-1256; doi:10.1093/jnci/djm081
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Published by Oxford University Press 2007.
ARTICLES |
Comparative Mortality for 621 Second Cancers in 29356 Testicular Cancer Survivors and 12420 Matched First Cancers
Affiliations of authors: Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD (CS, MH, BEC, LMB, RH, MG, LBT); Department of Clinical Research, Rikshospitalet-Radiumhospitalet Medical Centre, Oslo, Norway (SDF)
Correspondence to: Catherine Schairer, PhD, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Executive Plaza South, Rm 8020, Bethesda, MD 20892 (e-mail: schairec{at}exchange.nih.gov).
Background: Testicular cancer survivors, many of whom have undergone radiotherapy, are at substantial risk of second cancers. Treatment for testicular cancer may limit treatment options for second cancers, thereby adversely affecting survival after the second cancer. However, no data on outcomes of testicular cancer survivors with second cancers compared to patients with comparable first cancers exist.
Methods: Among 29356 white testicular cancer patients reported to the Surveillance, Epidemiology, and End Results (SEER) program (1973–2002), 621 developed a second cancer with known stage and were matched to a random sample of 12420 white male first cancer patients in the SEER program by cancer site, stage, diagnosis year, and age at diagnosis. Mortality was ascertained through 2002. Cancer-specific and all-cause mortality following second cancers were compared with those of matched first cancers, and rate ratios (RRs) were estimated using proportional hazards analysis. Survival functions were calculated using product-limit estimates.
Results: During the study period, 284 testicular cancer survivors with second cancers died, 191 from their second cancer; 5443 matched first cancer patients died, 3929 from their first cancer. Rate ratios for cancer-specific and all-cause mortality for second cancers compared with matched first cancers were 1.05 (95% confidence interval [CI] = 0.90 to 1.23) and 1.09 (95% CI = 0.96 to 1.23), respectively. However, among testicular cancer patients who were diagnosed during 1973–1979, an era in which radiation therapy was given at high doses and to the chest area, all-cause mortality following second cancers at sites below the diaphragm (79 deaths) and second lung cancers (29 deaths) was statistically significantly higher than that from matched first cancers (RR = 1.44, 95% CI = 1.13 to 1.83, and RR = 1.65, 95% CI = 1.12 to 2.42, respectively).
Conclusions: Mortality from second cancers following testicular cancer was similar to matched first cancers, except for selected tumors in the radiotherapy field among testicular cancer patients who were diagnosed during 1973–1979, a time when radiotherapy doses for treatment of testicular cancer were high and chest irradiation was an option in standard practice.
| CONTEXT AND CAVEATS Prior knowledge Survivors of testicular cancer are at high risk of developing second cancers. Study design Comparison of cancer and all-cause mortality among testicular cancer survivors who developed second cancers and patients with matched first cancers using data from the Surveillance, Epidemiology, and End Results program from 1973 to 2002. Separate analyses were performed for testicular cancer survivors who were diagnosed with testicular cancer during 1973–1979, when high-dose radiation therapy was common and irradiation to the chest area was a treatment option. Contribution Cancer-specific and all-cause mortality were similar between the groups overall. However, for diagnoses during 1973–1979, all-cause mortality among testicular cancer survivors with second cancers of the lung and at sites below the diaphragm was higher than that among patients with first cancers at these anatomic sites. Implications The mortality of testicular cancer survivors with second cancers was similar to that of patients with matched first cancers, but it was higher among testicular cancer survivors who were diagnosed with testicular cancer during 1973–1979 who developed second cancers at sites that were likely to have been in the radiotherapy treatment field during treatment for testicular cancer. Limitations The number of second cancers was small, and details of the treatments patients received and lifestyle risk factors were not available.
|
Manuscript received November 16, 2006; revised May 25, 2007; accepted June 26, 2007.
Related Article in JNCI
CiteULike 
Connotea 
Del.icio.us What's this?
J Natl Cancer Inst 2007 99: 1213.
This article has been cited by other articles:
|
|
 |
|
  X. Garcia-del-Muro, P. Maroto, J. Guma, J. Sastre, M. Lopez Brea, J. A. Arranz, N. Lainez, D. S. de Prado, J. Aparicio, J. M. Piulats, et al. Chemotherapy As an Alternative to Radiotherapy in the Treatment of Stage IIA and IIB Testicular Seminoma: A Spanish Germ Cell Cancer Group Study J. Clin. Oncol., November 20, 2008; 26(33): 5416 - 5421. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Feldman, G. J. Bosl, J. Sheinfeld, and R. J. Motzer Medical Treatment of Advanced Testicular Cancer JAMA, February 13, 2008; 299(6): 672 - 684. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Fossa Second Cancers among Survivors of Testicular Cancer: The Emerging Picture ASCO Educational Book, January 1, 2008; 2008(1): 423 - 426. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Outcomes of Second Cancers in Men with Histories of Testicular Cancer Journal Watch Oncology and Hematology, September 4, 2007; 2007(904): 1 - 1. [Full Text]
|
|